Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer

Inclusion

Pathologically confirmed invasive breast cancer with ER < 10%, PR < 10%, by IHC, HER2 1+ or 0 or FISH negative
Measurable (>= 1 cm) or assessable disease detectable by imagining or physical exam
Patients with bone only disease have measurable lesions on x-ray, MRI, or CT scan
Only one or no prior therapy for metastatic or recurrent breast cancer is allowed
Prior chemotherapy or radiation therapy is permitted but at least 2 weeks should elapse prior to study enrollment
Prior therapy with bevacizumab is permitted but at least 2 weeks should elapse prior to study enrollment
Prior therapy with bevacizumab is permitted but at least 28 days should elapse from the last bevacizumab treatment prior to study enrollment
ECOG PS or 0-1
Signed protocol specific informed consent prior to registration
Life expectancy greater than 3 months
Please contact study investigator and/or consult the protocol document for specific laboratory criteria
Tissue block available from primary breast cancer
Premenopausal women must have a negative serum or urine pregnancy test prior to starting on study treatment (post-menopausal is defined as > 6 months of amenorrhea prior hysterectomy)

Exclusion

More than or equal to 2 prior regimens for metastatic breast cancer
Leptomeningeal disease
Brain metastasis except for a solitary lesion that was resected or treated with gamma knife with no residual disease on CT or MRI or received whole brain RT and f/u MRI was normal with no residual neurologic deficit
History of interstitial lung disease (ie pneumonitis, pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest computerized tomography (CT) scan
History of irreversible neuropathy
Another malignancy other than carcinoma in situ of the cervix or skin cancer
Active uncontrolled bacterial viral or fungal infection
Active pregnancy or breast feeding
Patients with pre-existing neuropathy >= grade 2
History of myocardial infarction, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia
Patients with previous history of CTCAE grade >= 3 hypersensitivity to paclitaxel or Cremophor EL are not eligible